REIG JOFRE is a pharmaceutical company born out of a strong belief in making health universally accessible delivering everything from basic care solutions to the most innovative treatments to people around the world. To offer pioneering, high-impact solutions, the company relies on state-of-the-art production technology, ongoing collaboration with innovative companies, researchers, and startups, and sustained investment in R&D. Since 1929, REIG JOFRE has been researching, developing, manufacturing, and marketing pharmaceutical products essential to people’s health across three major areas: Pharmaceutical Technologies (antibiotics and sterile injectable products for hospital use), Specialty Pharmacare (dermatology and osteoarticular therapies) y Consumer Healthcare (ENT and dietary supplements to support health and wellbeing). Reig Jofre has thrived on BME, not only consolidating its position as one of Spain’s leading listed pharmaceuticals companies, but also building up an impressive footprint across Europe. BME spoke to Ignasi Biosca, CEO of Reig Jofre, about how the company has flourished on the Exchange.
A decade ago, Reig Jofre, a leading Spanish pharmaceuticals company, joined BME following a reverse merger. The Exchange reflects on how this has enabled Reig Jofre to access new financing sources and fund its ambitious growth plans.
About Reig Jofre
Why Spain?
Reig Jofre wanted greater access to capital and better visibility and credibility with investors, both of which are fundamental pre-requisites to achieving scale, and diversification into new markets and products.
Endowed with an expansive network of local and international investors – BME was well-positioned to support Reig Jofre’s growth objectives. Spain’s robust regulatory framework and high corporate governance and transparency standards, are also a strong selling point.
Going from Private to Public
Reig Jofre’s listing was not an IPO in the conventional sense, but rather a reverse merger with a company that was already publicly traded on BME. “We indirectly entered the capital markets through an already listed company –” said Biosca.
The transaction was structured so that it allowed the original family owners of Reig Jofre to retain majority control of the company, whilst also letting the business tap the public markets for additional capital.
Opening up the company’s capital allowed us to welcome new travel companions while keeping the founding family as long-term supporters of the project
Ignasi Biosca, CEO, Reig Jofre
Going from Strength to Strength
Since boosting its profile among equity investors, Reig Jofre has realised a number of its strategic objectives.
Raising financing on the capital markets allowed Reig Jofre to diversify into new markets and products, most notably food supplements and Osteoarticular portfolio, having historically been focused on just pharmaceuticals. It also enabled Reig Jofre to build a new injectables plant in Barcelona.
This access to capital markets has helped the company cement its resilience even further at a time when volatility has been rising.
In addition, it also had a positive impact on Reig Jofre’s production capacity.
“We are a better known company and are more internationally recognised,” noted Biosca. He continued: “The transaction allowed us to become a more innovative company in terms of products and pharmaceuticals technologies – our technology is far superior to what we had in 2015. We are a much braver company and willing to take risks, albeit very measured ones.”
The results speak for themselves – “We have basically doubled in size as a company,” said Biosca. “A decade on the market has given us discipline and vision. We continue investing in technology and talent to turn innovation into real health, with a purpose that remains unchanged - bringing the science that matters to more people — safely, with quality and trust,” he added.
With private markets starting to look a bit shaky and the European IPO space tentatively recovering, expect more private companies to explore the merits of listing over the next few months.
About Ignasi Biosca
Ignasi Biosca Reig Born in Barcelona in 1968. Telecommunications Engineer from the Polytechnic University of Catalonia, Barcelona. He has a Master's degree in Communication Networks from the École Supérieure d'Ingénieurs Télécom Paris Tech in Paris and an MBA from the IESE Business School in Barcelona. University of California, Berkeley (USA), where he experienced the dot-com boom.
Following a career in digital media, he became CEO of REIG JOFRE, a pharmaceutical company founded by his grandfather in 1929. Under his leadership, the company has consolidated its position as the fifth-largest Spanish pharmaceutical company by turnover. It is listed on the stock exchange (RJF) and has more than 1,400 employees, four development and production centres across Europe, a direct presence in eight countries and distribution in over 70.
Reig Jofre’s Differential Value Versus to Other Companies in the Sector
Reig Jofre stands out as a growth-driven pharmaceutical company with a compounded annual expansion of 11% over the past five years and a clear shift toward profitable, operationally excellent growth. Its distinctiveness lies in a double commitment to innovation—both in products and brands, and in advanced industrial technologies—supported by a strong, proprietary manufacturing footprint. With a dual business model that balances proprietary products and CDMO services, as well as chemical and increasingly biological capabilities, the company has become more resilient, international, technologically sophisticated, and strategically ambitious during its decade as a listed firm. Its extensively diversified portfolio—where no product exceeds 10% of sales—spans pharmaceuticals, cosmetics, and nutritional supplements, all aligned with its purpose of delivering essential, science-based solutions to as many people and markets as possible through synergistic channels such as hospitals, medical practices, and pharmacies.
Listing on BME Exchange
With BME by your side, the journey from going public to thriving as a listed company becomes seamless. Learn more about listing on BME.